The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public notice concerning the unauthorized sale of unregistered Seretide Accuhaler on Instagram and various online platforms.
Following an investigation, NAFDAC officials visited two addresses, leading to the discovery of an unregistered Seretide Accuhaler at 14 Lanre Hassan Street, off Karimu Laka, Egbeda Lagos.
The unregistered medication was traced back to Vidana Logistics, a subsidiary of Vidana Integrated Nig. Ltd, which claimed to have sourced the products from an Indian doctor. Ongoing investigations are aimed at uncovering the import route and implementing measures to block such entry points.
In a risk statement, NAFDAC emphasized the dangers associated with the illegal marketing of medicines, highlighting the potential risks to public health due to the absence of guarantees for safety, quality, and efficacy in unregistered products.
Key Points:
- NAFDAC registers the original brand of Seretide Accuhaler with the registration number 04-6850.
- Seretide is a medication commonly used for asthma and chronic obstructive pulmonary disease (COPD) treatment in individuals requiring regular therapy.
- NAFDAC urges distributors, retailers, and consumers to exercise caution and vigilance, emphasizing the importance of verifying the authenticity and physical condition of Seretide Accuhaler before purchase or use.
- Individuals possessing the unregistered product are advised to surrender it to the nearest NAFDAC office.
- NAFDAC encourages individuals who have used the product and experienced adverse reactions to seek immediate medical advice from qualified healthcare professionals.
The public is urged to report any suspicions of the distribution and sale of unregistered Seretide Accuhaler to the nearest NAFDAC office, call, or use the provided email address.
Healthcare providers and patients are also encouraged to report any adverse events or side effects related to the use of the product through various channels, including the E-reporting platforms on the NAFDAC website, the Med-safety application available on Android and IOS stores, or via email.
